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LETTERS TO THE EDITOR
Expression
and
function
of
cathelicidin
hCAP18/LL-37 in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is characterized
by the accumulation of clonal B-cells in peripheral blood
and lymphoid tissues.1 Circulating CLL cells are nondividing B lymphocytes, but a significant fraction of the
clone proliferates in lymphoid tissues where they receive
a plethora of signals from the microenvironment that
promote their survival and expansion.2 Cathelicidins are a
family of proteins with antibacterial functions mainly
expressed by neutrophils, macrophages and epithelial
cells.3 In humans, the only member of this family,
hCAP18, is encoded by the gene CAMP. The cleavage of
hCAP18 generates the antimicrobial peptide LL-37,
which has been recently implicated in the promotion of
tumor growth, through direct stimulation of malignant
cells, initiation of angiogenesis and recruitment of
immune cells.4 In this study, we investigated the role of
hCAP18/LL-37 in CLL.
Clinical features of analyzed patients are shown in the
Online Supplementary Table S1. By gene expression analysis, we found that CAMP is up-regulated in CLL cells
compared to B cells from age-matched healthy donors
(HD) (Online Supplementary Figure S1), and this was confirmed by qRT-PCR (Figure 1A). Interestingly, when samples were discriminated according to their immunoglobulin heavy chain variable region (IGHV) mutation status,
those with unmutated IGHV (poor clinical outcome, UCLL) showed significantly higher levels than those with
mutated IGHV (better outcome, M-CLL). Similarly,
leukemic cells from patients in Rai III/IV stages expressed
higher levels of hCAP18 mRNA compared to indolent Rai
0 patients (Figure 1B), suggesting that transcription of
CAMP is related to an aggressive clinical phenotype.
Nevertheless, flow cytometry analysis, using polymorphonuclear cells (PMN) as a positive control, did not
reveal hCAP-18/LL-37 protein expression in circulating
CLL cells or B lymphocytes from healthy donors (Online
Supplementary Figure S2).
Given that CLL cells in lymphoid tissues possess a distinct phenotype, with enhanced expression of anti-apoptotic and activation markers compared to circulating
cells;5 we looked for hCAP18/LL-37 in bone marrow
biopsies. Figure 1C shows that a proportion of leukemic
cells (CD20+) and almost all myeloid cells (CD68+) cells
expressed hCAP18/LL-37. These results suggest that signals from the microenvironment promote the expression
of hCAP-18/LL-37 protein in CLL cells. To assess this
possibility we stimulated circulating CLL cells with different well-known stimuli, such as CD40L, CpG, immobilized anti-IgM, interleukin (IL)-4 (IL-4) and IL-15. Results
show that these stimuli up-regulated the transcription of
CAMP (Figure 1D) and, more importantly, those stimuli
that were most effective in increasing hCAP18 mRNA,
i.e., CpG+IL15 and CD40L+IL4, induce the expression of
hCAP18/LL-37 protein (Figure 1E). We also observed a
significant though moderate correlation between mRNA
and protein levels of hCAP18/LL-37 after cellular activation (Online Supplementary Figure S3). Compared to neutrophils, the intracellular expression of hCAP18/LL-37 in
activated CLL was modest. However it should be taken
into account that hCAP18/LL-37 is stored in neutrophils
granules at very high concentrations (0.6 mg/106 cells),6
while it appears to be released to supernatant by activated CLL cells (Figure 1F).
hCAP18/LL-37 has been shown to participate as a
tumor promoting factor in breast and lung cancers and in

pancreatic ductal adenocarcinoma.4,7 In those settings,
hCAP18/LL-37 acts mainly as a growth factor inducing
tumor cell activation, survival and proliferation. Since
CLL cells proliferate minimally in vitro, even upon strong
stimulation, we assessed if LL-37 could induce leukemic
cell activation and inhibit spontaneous and drug-induced
apoptosis. We found that incubation of CLL cells with
LL-37 at 5 or 10 mM did not increase the expression of
activation markers (not shown), but significantly delayed
spontaneous apoptosis of leukemic cells as evaluated by
binding of Annexin V (Figure 2A-B). These concentrations are found at sites of inflammation, like bronchoalveolar lavage fluid from infants with pulmonary
infections8 or psoriatic skin lesions.9 Of note, LL-37 not
only inhibited spontaneous CLL apoptosis but also interfered with that induced by ABT-199 or fludarabine,
agents currently employed for CLL treatment1 (Figure 2CD and Online Supplementary Figures 4-5). In addition to
AnnexinV staining, inhibition of apoptosis by LL-37 was
corroborated analyzing caspase 3 cleavage (Figure 2E)
and BCL-2 expression (Online Supplementary Figure S5B).
Because delay of neutrophil apoptosis by LL-37 has been
reported to depend on two different receptors: FPRL1
and P2X7,10 we tested if WRW4 (FPRL1 antagonist) or
KN-62 (P2X7 inhibitor) could counteract the protective
effect of LL-37. Figure 3A shows that none of these
agents interfered with LL-37 activity indicating that neither FPRL1 nor P2X7 were involved.
LL-37 can also interact with CXCR4,11 the receptor for
the chemokine CXCL12, which plays an important role
in CLL by promoting the migration of leukemic cells to
lymphoid tissues and improving their survival.12
Therefore, we determined if CXCR4 was involved in the
anti-apoptotic pathway triggered by LL-37. We found
that an antibody directed to CXCR4 that blocks CXCL12
engagement impaired LL-37 protection (Figure 3B).
Furthermore, confocal microscopy shows co-localization
of LL-37 and CXCR4 on the cell membrane indicating
that both molecules are in the same patches on CLL surface (Figure 3C). Finally, we evaluated CXCR4 endocytosis since this is a mandatory step for chemokine receptors
upon binding cognate chemokine, in this case CXCL12.
The interaction of CXCR4 with LL-37 at 37ºC led to
downregulation of CXCR4 from the CLL cell surface
(Figure 3D). Altogether, these results suggest that CXCR4
could be acting as a LL-37 receptor on CLL cells.
Since it has previously been reported that LL-37
enhances the chemotactic responsiveness of hematopoietic progenitors to low doses of CXCL12,11 we evaluated
if this was also true for CLL cells. To address this, we
used transwell chambers and assessed leukemic cell
migration towards a suboptimal concentration of
CXCL12 (25 ng/mL), with or without LL-37 (5 mM). As
was the case for hematopoietic progenitors, LL-37
increased the migratory response of CLL cells to
CXCL12. Of note, LL-37 did not induce chemotaxis of
CLL cells by itself, as demonstrated in neutrophils acting
through FPRL110 and in keratinocytes through transactivation of the epidermal growth factor receptor13 (Figure
3E).
Accumulating evidence supports pro- or anti-tumorigenic roles for hCAP18/LL-37 in various types of human
cancer, e.g., pro-tumor in ovarian, lung and breast cancer
and in malignant melanoma, and anti-tumor in colon and
gastric tumors.4 In agreement with its inflammatory and
pro-angiogenic activity, hCAP-18/LL-37 expression in
most solid tumors correlates with increased leukocyte
infiltration and microvessel density. In breast and lung
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Figure 1. hCAP18/LL-37 expression in chronic lymphocytic leukemia cells. (A) Left panel: hCAP18 mRNA expression was evaluated in purified B-cells from
healthy donors (HD) (n=7) and chronic lymphocytic leukemia (CLL) cells (n=41) samples by qRT-PCR. Results were normalized to b-actin human gene and are
represented as relative units (2-Δctx103). Statistical analysis was performed using Mann-Whitney test. Shown are individual values and mean ± standard error
of the mean (SEM). Right panel: hCAP18 mRNA expression on CLL cell samples discriminated based on their immunoglobulin heavy chain variable region (IGHV)
mutational status. Unmutated (U-CLL) n= 21, Mutated (M-CLL) n=20. (B) The average expression of mRNA hCAP18 in CLL cell samples was calculated and
patients were separated into two groups: those with hCAP18 levels below the average (low-hCAP18) and those with hCAP18 levels above the average (highhCAP18). c2 test showed a statistically significant association between hCAP18 expression and CLL clinical stage (Rai staging). (C) Expression of hCAP18/LL-37
on bone marrow biopsies from CLL patients. Samples were doubled-stained to identify LL-37 in myeloid cells (CD68+) and CLL cells (CD20+) as detailed in the
Online Supplementary Materials and Methods. Shown are representative pictures for haematoxylin and eosin (H/E) staining, hCAP18 single staining and CD68+
or CD20+/hCAP18 double staining, n=5 (left panel). Image magnification: 600x. Arrow heads represent hCAP18 single positive cells (a) or double positive
(CD20/hCAP18) cells (b). In the right panel, pie charts displaying the total percentage of hCAP18 positive cells and the contribution of each cell type
(CD68+,CD20+ and others) are shown (D) hCAP18 mRNA expression in CLL cells stimulated with CpG (5 mg/mL), CpG + IL-15 (10 ng/mL), immobilized anti-IgM
antibody (Ab) (0.1 µg/mL), anti-IgM Ab + IL-4 (15 ng/mL), anti-IgM Ab + CD40L (500 ng/mL), CD40L or CD40L + IL-4 for 48 hours (h) at 37ºC. Results are
expressed as fold increase compared to control (unstimulated condition). Statistical analysis was performed using Friedman test and Dunn’s multiple comparison test. Shown are individual values and mean ± standard error of the mean (SEM). Blue dots correspond to M-CLL and red dots to U-CLL samples. Asterisks
represent P<0.05. E. Intracellular expression of hCAP18/LL-37 in CLL cells activated with CpG + IL-15 or CD40L + IL-4 for 48 h at 37ºC. Results are expressed
as the ratio of median fluorescence intensity (MFI) of hCAP18/LL-37 to MFI of isotype control in CD19+ cells (blue dots: M-CLL, red dots: U-CLL) or in PMN (positive control). Individual values and mean ± SEM are shown. F. LL-37 concentration in culture supernatants of activated CLL-cells quantified by enzyme linked
immunabsorbant assay (ELISA). Statistical analysis was performed using Friedman test and Dunn’s multiple comparison test (P<0.05). Shown are individual values and mean ± SEM. (blue dots: M-CLL, red dots: U-CLL).
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Figure 2. LL-37 inhibits spontaneous and ABT-199 induced apoptosis of chronic lymphocytic leukemia cells. Peripheral blood mononuclear cells (PBMC) samples from chronic lymphocytic leukemia (CLL) patients were incubated with LL-37 (2.5-10 mM) for 48 hours (h) 37ºC. Cells were stained with PC5-anti-CD19
mAb and AnnexinV-FITC and analyzed by flow cytometry. (A) Shown are representative CD19 versus AnnexinV dot plots (blue dots: M-CLL, red dots: U-CLL) and
the percentage of apoptotic cells (mean ± standard error of the mean [SEM], n=12). (B) PBMC samples from CLL patients were incubated with ABT-199 (0.01
μM) with or without LL-37 (5 mM) for 48 h at 37ºC. (C-D) Apoptosis was assessed by flow cytometry as described in (A). Depicted are representative CD19 versus
AnnexinV dot plots and the percentage of apoptotic cells (mean ± standard error of the mean [SEM], n=13). Statistical analysis was performed using Friedman
test and Dunn’s multiple comparison test (P<0.05). (E) Leukemic cells were treated with ABT-199 (0.1 mM) for 18 h with or without LL-37 (5 mM). The activation
of the apoptotic program was analyzed by caspase-3 cleavage and flow cytometry. Shown are representative histograms (n=5).
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Figure 3. Role of CXCR4 in LL-37 effects on chronic lymphocytic leukemia cells. Peripheral blood mononuclear cells (PBMC) from chronic lymphocytic leukemia
(CLL) patients were incubated with WRW4 (1 mM), KN-62 (1 mM) or both for 30 min before adding LL-37 (5 mM). Cells were cultured for 48 hours (h) at 37ºC
and apoptosis was evaluated as described in Figure 2. (A) The percentages of apoptotic CLL cells are shown (mean ± standard error of the mean [SEM], n= 5).
Statistical analysis was performed using Friedman test and Dunn’s multiple comparison test (P<0.05). (B) PBMC from CLL patients were incubated with antiCXCR4 Ab (10 mg/mL) for 30 min before adding LL-37 5 mM. Cells were cultured for 48 h at 37ºC. A fresh aliquot of anti-CXCR4 was re-added at 24 h. Apoptosis
was evaluated at 24 and 48 h as described in Figure 2. Shown are the percentages of apoptotic cells (mean ± SEM, n=6). Statistical analysis was performed
using Friedman test and Dunn’s multiple comparison test (P<0.05). (C) CLL cells were incubated for 30 min with LL-37 (5 mM), then fixed with 4% paraformaldehyde and labeled with rabbit anti-LL-37 IgG followed by Dy-Light 488-anti-rabbit IgG (green) and anti-CXCR4-PE IgG (red). Colocalization areas are indicated by
the arrowheads. The bar indicates 15 mm. (D) Time-dependent downregulation of CXCR4 on CLL cells induced by LL-37. CLL cells were incubated with LL-37
(5 mM) at 37ºC for the indicated time and the expression of membrane CXCR4 was evaluated by flow cytometry. Results are expressed as mean flouresence
intensisty (MFI) (mean ± SEM, n=5). Statistical analysis was performed using Friedman test and Dunn’s multiple comparison test (P<0.05). (E) LL-37 enhances
the migration of LLC cells towards CXCL12. CLL cells (2x106 cells/mL) were seeded in the upper chamber of transwell plates to evaluate their migration to the
lower compartment in response to CXCL12 (25 ng/mL) in the presence or absence of LL-37 (5 mM). Cells were incubated for 120 min, recovered from the lower
chamber and quantified by flow cytometry. The migration index was calculated as the subtraction of the number of CD19+ cells that migrated spontaneously
(control without chemokine) from the number of CD19+ cells that migrated in the presence of CXCL12 and normalized to the input. Shown are mean ± SEM
(n=7). Statistical analysis was performed using Friedman test and Dunn’s multiple comparison test (P<0.05). In all cases red dots represent U-CLL and blue
dots M-CLL.
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cancers, exogenous LL-37 promotes cell proliferation and
metastasis,4 but it induces G0/G1 cell cycle arrest in gastric cancer cells, suggesting that the effect of hCAP18/LL37 depends on the tissue origin of the tumor. Moreover,
it is important to consider that hCAP18/LL-37 can also be
expressed by stromal and myeloid cells in the microenvironment. In fact, malignant cells are able to promote the
expression of hCAP18/LL-37 by tumor associated
macrophages as occurs in pancreatic ductal adenocarcinomas where the secreted peptide contributes to tumor
progression.7 Similarly, in a murine model of prostatic
cancer, overexpression of CAMP in tumor cells favors the
differentiation of early myeloid progenitors into protumorigenic M2 macrophages.14
Here we show that, unlike normal B lymphocytes,
leukemic B cells from CLL patients express hCAP18
mRNA and that this expression associates with poor
prognosis and disease stage. Interestingly, we found that
circulating CLL cells can produce and release
hCAP18/LL-37 protein upon in vitro activation with
microenvironmental stimuli and this observation was
supported by bone marrow immunohistochemistry. In
vitro, exogenous LL-37 delays CLL cell apoptosis, both
spontaneous and apoptosis induced by chemotherapeutic
agents. As an antimicrobial peptide, the main function of
LL-37 is to induce bacterial lysis via the formation of
transmembrane pores.15 Cellular membranes associated
with cholesterol, such as those from human cells, are
resistant to LL-37 toxicity unless supraphysiological concentrations are used. By contrast, LL-37 has antiapoptotic
effects in a variety of cells including neutrophils through
FPRL1 and P2X7.10 We have shown that these two receptors are not involved in CLL cell protection by LL-37, but
rather this depends on CXCR4, a key receptor for CLL
cell survival and traffic. Of note, LL-37 was able to
enhance leukemic cell migration towards suboptimal
concentrations of CXCL12.
In conclusion, our results suggest that hCAP18/LL-37
may have an active role in the CLL-tumor microenvironment by increasing leukemic clone retention and survival
in lymphoid tissues.
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